Du är här

2014-04-30

Medigene AG: Medigene has appointed Prof. Dr Dolores J. Schendel to the Executive Board as Chief Scientific Officer

Medigene AG / Medigene has appointed Prof. Dr Dolores J. Schendel to the
Executive Board asChief Scientific Officer . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Martinsried/Munich, 30 April 2014.
Biotech company Medigene AG (Frankfurt: MDG1, Prime Standard) is pleased to
announce that the company's Supervisory Board has as planned appointed Prof.
Dr.Dolores J. Schendel as Chief Scientific Officer of Medigene AG effective
1 May 2014. Former Director of the Institute of Molecular Immunology at the
Helmholtz-Zentrum München and Managing Director of Trianta Immunotherapies
GmbH, Prof. Schendel will now be the Executive Board member responsible for
research and development at Medigene. She will continue as Member of the
Management Board of Trianta Immunotherapies GmbH, which was acquired by
Medigene in January 2014. With the appointment of Prof. Schendel, the
Executive Board of Medigene AG has increased to three members.

Prof. Dr.Horst Domdey, Chairman of the Supervisory Board of Medigene AG
, comments: "We are proud to have an exceptional immunologist and experienced
manager such as Prof. Dolores Schendel joining the Executive Board of
Medigene. Her internationally recognised scientific expertise and management
skills, as well as the highly innovative immunotherapy technologies she has
developed with her team, will add significant value to Medigene AG."

Prof. Dr.Dolores Schendel, Executive Board member responsible for research and
development at Medigene AG from 1 May 2014:
"I am very much looking forward to working together with the experienced
Medigene team on the continued development of technologies and drug
candidates, which could help improve the lives of seriously ill patients in
future. The close collaboration with Medigene has been very positive so far,
both from a personal and a professional standpoint. I am certain that the
merger and integration of the two companies, Medigene and Trianta, which has
almost been successfully concluded, offers great potential for the future."

About Prof. Dolores J. Schendel:
Prof. Dolores J. Schendel, Managing Director of Trianta Immunotherapies GmbH,
has been Director of the Institute of Molecular Immunology of the German
Research Center for Environmental Health since 1998 and has held an adjunct
professorship in immunology at the Ludwig Maximilian University of Munich
since 1986. Her research focuses on human immunology and immunotherapy. She
has led preclinical groups for GMP process development and immune monitoring
for clinical studies. Prof. Schendel has experience in building and guiding
diverse teams required to initiate clinical studies of new immunotherapy
strategies based on DC vaccines and adoptive T cell therapy. She has served
as a Member of the German Cancer Aid Grants Review Panel and as Chair of a
Life Science Study Panel of the European Research Council.

About Trianta:
Trianta Immunotherapies GmbH, a wholly owned subsidiary of Medigene AG, is at
the forefront of personalized T cell immunotherapy, focussing on next
generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor
(TCR)-based adoptive cell therapy and T cell-targeted antibodies (TABs).
Trianta Immunotherapies was founded late 2013 as a spin-off of the Helmholtz
Zentrum München, the German Research Centre for Environmental Health. Trianta
exploits the therapeutic and commercial potential of T cell-focused therapies
developed by the team of Prof. Dolores J. Schendel at the Helmholtz Zentrum
Munich, in collaboration with Prof. Thomas Blankenstein at the Max Delbrück
Centre for Molecular Medicine, Berlin. The team of Trianta pursues three
complementary immunotherapeutic strategies to target various tumour types and
stages. Each one is focused on T cells, a type of white blood cell that plays
a pivotal role in immunity. Trianta Immunotherapies was acquired by Medigene
in January 2014.

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. Medigene concentrates on
the development of personalized T cell immunotherapies with focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, Veregen®, which is distributed by
commercial partners companies. Medigene has various drug candidates in
clinical development and it is developing highly innovative treatment
platforms. For more information, please visitwww.medigene.com.

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®EndoTAG®and Veregen®are registered
trademarks of Medigene AG. Polyphenon E®is a trademark of Mitsui Norin Co.,
Ltd. These trademarks may be owned or licensed in select locations only.

Contact
Julia Hofmann, Claudia Burmester
Tel.: +49 - 89 - 20 00 33 - 33 01
Email:investor@medigene.com

To unsubscribe from the press release distribution list, please go
to:http://www.medigene.de/unsubscribe

Press release as PDF
http://hugin.info/132073/R/1781307/609385.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#1781307

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.